Pfizer (NYSE:PFE) Trading Up 2% – What’s Next?

Pfizer Inc. (NYSE:PFE) shares traded up 2% during trading on Tuesday . The company traded as high as $28.58 and last traded at $28.5280. 30,909,403 shares traded hands during trading, a decline of 26% from the average daily volume of 41,964,996 shares. The stock had previously closed at $27.97.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts highlight Pfizer’s oncology portfolio, broader diversification and relatively attractive valuation compared with Bristol Myers Squibb, suggesting potential upside if new cancer medicines improve growth. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Coverage continues to focus on Pfizer’s pipeline and whether new medicines can reset the company’s growth story after pandemic-product declines. A successful launch cycle could support earnings before major patent expirations arrive. Can New Medicines Reset the Growth Story?
• Positive Sentiment: Pfizer has begun the European Medicines Agency review for its Lyme disease vaccine, advancing a potential future product opportunity and providing another pipeline catalyst. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Neutral Sentiment: Commentary describes PFE as a defensive healthcare name benefiting from renewed interest in pharmaceutical pipelines, but the stock’s performance remains tied to execution and evidence that research investments can produce sustainable growth. Why is Pfizer in Focus?
• Neutral Sentiment: Brokerage coverage remains cautious, with Pfizer receiving a consensus “Hold” recommendation, indicating limited conviction that near-term catalysts will outweigh longer-term risks. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Dividend-focused analysis warns that Pfizer’s payout ratio above 100% reflects pressure on earnings coverage. Although the article says investors should look beyond that single metric, rebuilding profits ahead of patent expirations remains the key risk to dividend confidence. The Most Concerning Thing About Pfizer’s Dividend Isn’t What You Think

Analyst Ratings Changes

A number of brokerages recently issued reports on PFE. Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Guggenheim reduced their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Weiss Ratings lowered Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 17th. Finally, Citigroup raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Down 0.6%

The stock has a market cap of $160.36 billion, a P/E ratio of 37.03 and a beta of 0.34. The company’s fifty day moving average price is $25.44 and its 200-day moving average price is $26.29. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business earned $0.78 EPS. Pfizer’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of PFE. Evolution Wealth Management Inc. lifted its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth $26,000. Keb Asset Management LLC purchased a new position in Pfizer during the 2nd quarter worth $26,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares in the last quarter. Finally, Field & Main Bank purchased a new stake in Pfizer in the second quarter valued at about $27,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.